SLU-PP-332 500 mcg 60 caps

SLU-PP-332 - what it is and how it works

SLU-PP-332 is experimental estrogen-related receptors (ERR) agonist - A group of nucleolar nuclear receptors involved in the regulation of Energy metabolism, mitochondrial function and fat consumption. The substance is classified as „exercise mimetic”, a pharmacological compound that, in preclinical models, activates similar metabolic pathways as intense physical activity, leading to Increased expression of genes related to fatty acid oxidation, mitochondrial biogenesis and muscle endurance capacity. 

Mechanistically, the SLU-PP-332 works by. Binding to ERRα, ERRβ and ERRγ receptors, with the highest activity toward ERRα, which stimulates intracellular pathways regulating mitochondrial metabolism and the expression of genes related to aerobic muscle adaptation. In activated ERRs, there is an increase in the expression of proteins involved in oxidative phosphorylation, fat beta-oxidation and glucose transport, which resembles the metabolic adaptations observed after intense exercise.

SLU PP 332 vs. weight loss

Based on available preclinical studies, SLU-PP-332 has not been directly developed as a classical weight-reduction agent, but its mechanism of action suggests indirect potential to influence the body's energy balance. By activating ERR receptors and enhancing metabolic pathways related to mitochondrial function and fatty acid oxidation, the compound leads to increased energy expenditure in muscle tissue.

In animal models, improvements in metabolic parameters, increased energy consumption, and changes in muscle fiber profile toward a more aerobic phenotype have been observed, which promotes a better use of energy substrates, including lipids. Such metabolic adaptations can experimentally reduce obesity-promoting metabolic disorders and indirectly affect weight control.

However, it should be emphasized that Weight loss was not the primary endpoint of the SLU-PP-332 study, and all observations are in preclinical models only. The lack of clinical data makes it impossible to assess the efficacy and safety of the compound in the context of weight reduction in humans, so the potential effect of SLU-PP-332 on weight loss remains at the stage of research hypotheses and requires further clinical studies.

SLU-PP-332 - study status and dosage.

SLU-PP-332 remains at preclinical research stage. No human clinical trials have been conducted, and dosage information relates only to animal models, mainly mice. The compound has no approved therapeutic guidelines or clinical dosage in humans.

Various dosage regimens have been used in preclinical models, most commonly from 30 mg/kg to 50 mg/kg orally to study metabolic effects, muscle adaptations and „exercise mimetic action”.

SLU-PP-332 - metabolic and „exercise mimetic” effects”

Preclinical studies have shown that SLU-PP-332 activates the A genetic program similar to that induced by aerobic training, which results in:

• Increase fatty acid oxidation and metabolic energy consumption in muscle, including the expression of genes like Pdk4 and Ddit4 linked to metabolic adaptation.
• A change in the phenotype of muscle fibers toward more aerobic (oxidative type IIa), which is associated with improved muscle endurance capacity.
• Increased physical endurance and running time in animal models, suggesting the potential to improve physical abilities even without exercise training.

These activities are often referred to as „pharmacological mimicry of exercise”.” (pharmacological exercise mimetic).

SLU-PP-332 - security

Because SLU-PP-332 has not been clinically studied in humans, safety profile in the context of human therapy is unknown. In preclinical models no acute toxic effects have been reported at the doses and times studied, but side effects related to interference with metabolic and mitochondrial regulation are possible. Potential risks are still under investigation and include Changes in enzymatic parameters, organ function and metabolic response.

SLU-PP-332 - price and availability

SLU-PP-332 is not authorized as a medicinal product and does not exist as a substance available in pharmacies. As an experimental compound and research reagent, it is sometimes offered in the laboratory trade exclusively for scientific and research purposes, without human approval. Its availability and price depend on reagent suppliers, and use outside scientific research is not recommended or legal.

SLU-PP-332 - where to buy?

SLU-PP-332 is not approved for marketing as a medicinal product or dietary supplement and is not available in pharmacies. It can only be offered as reagent designed for scientific research and laboratory analysis, available from select research & development suppliers. These products are not intended for use in humans or for therapeutic purposes.

Functional Summary

In short, the SLU-PP-332 is. An experimental small-molecule substance that acts as an ERR agonist, with the potential to:

• increase immunity and metabolic endurance,
• activation of metabolic pathways Typical of intense exercise,
• improve fat oxidation and mitochondrial function,
• potential impact on Metabolic signals associated with obesity and insulin resistance,

however, everything is based on preclinical data and requires further clinical studies before therapeutic evaluation in humans.

Sources/literature for SLU-PP-332:

PubMed (2023) - Identification of SLU-PP-332 as a pan-ERR agonist with an „exercise mimetic” effect in muscle.
https://pubmed.ncbi.nlm.nih.gov/36988910/

PubMed / J Pharmacol Exp Ther (2024) - ERR agonist effects in mouse metabolic models.
https://pubmed.ncbi.nlm.nih.gov/37739806/

ACS Chemical Biology (2023) - Identification and molecular mechanism of SLU-PP-332 against ERR receptors.
https://pubs.acs.org/doi/10.1021/acschembio.2c00720

Frontiers in Physiology (2025) - A review of the role of ERRs and the potential of agonists like SLU-PP-332 as „exercise mimetics” in the metabolic and aging context.
https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2025.1616693/full